PTC Therapeutics is expanding its rare disease portfolio by acquiring the ST-920 Fabry disease program from Sangamo Therapeutics for $111 million upfront plus potential milestones. This acquisition provides PTC Therapeutics with a late-stage gene therapy asset, leveraging its existing infrastructure and potentially accelerating its market position in Fabry disease.
PTC Therapeutics (PTCT) is acquiring the ST-920 Fabry disease program from Sangamo Therapeutics through a competitive bankruptcy auction. This is a significant corporate catalyst for PTCT as it adds a one-time administered AAV gene therapy to its rare disease pipeline, with a BLA submission expected in Q4 2026. The $111 million upfront payment, plus up to $100 million in contingent milestones, represents a substantial investment. This move is expected to leverage PTCT's existing regulatory and commercial infrastructure, potentially accelerating its market entry and strengthening its position in the Fabry therapy market. For traders, this presents a short-term opportunity for PTCT as the market reacts to the strategic expansion, with long-term implications tied to the successful development and commercialization of ST-920.